Abstract
Janiemycin is a new basic peptide antibiotic produced by a strain of Streptomyces macrosporeus ATCC 21, 388. It is a bactericidal compound, active primarily against gram-positive bacteria. In model murine infections with Streptococcus pyogenes C203 and Diplococcus pneumoniae Type 3, janiemycin is as active as penicillin G; moreover, a single subcutaneous dose provides prolonged protection (at least 48 hours) to mice infected with S. pyogenes C 203. Janiemycin and enduracidin are apparently related, but they are easily distinguished by the absence of α-amino-3, 5-dichloro-4-hydroxyphenylacetic acid from the hydrolysate of janiemycin.
